Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo

Articles and Videos

December 4, 2018
The Promise of Cannabinoids to Treat Pain
The focus of treating pain over the last decade has led to the emergence of a number of opioid drugs. Since their introduction, this method...
Source: Money Inc
Read More
November 13, 2018
Cannabinoid-based Therapeutics: Terpenes and Testing Magazine
Looking through the Telescope onto the Horizon: InMed Pharmaceuticals Nearly every week, there is another cannabis-themed headline such as “New Study Says 97% of Elderly...
Source: Terpenes and Testing Magazine, by Jason S. Lupoi, PhD
Read More
November 4, 2018
How Biosynthesis of Cannabinoids Could Impact the Cannabis Industry
A highly disruptive technology that I have discussed over the past few years appears to be gaining traction. Biosynthesis, an alternative, natural method of producing...
Source: New Cannabis Ventures
Read More
November 3, 2018
BTV Interview with InMed CEO, Eric Adams Full Version
Source: BTV
Read More
November 2, 2018
InMed Biosynthesis Platform – Potential to Produce High Quality Pharmaceutical-Grade Cannabinoids Efficiently
InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical...
Source: BTV
Read More
November 2, 2018
Eric A. Adams talks with BTV about InMed’s biosynthesis of cannabinoids
In this video, InMed CEO Eric A. Adams speaks with BTV about InMed's focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company's proprietary...
Source: BTV
Read More
« Previous 1 2 3 4 5 Next »

Overview

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: